Stem cell
-
DATABASE (52)
-
ARTICLES (55)
Founder of TreeFrog Therapeutics
Kévin Alessandri is CEO, CTO and co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Alessandri spent two years as a post-doctoral fellow at Bordeaux’s Institut d’Optique. During 2014 and 2015, he completed a post-doctorate at the University of Geneva, focused on developing 3D printed microfluidics systems to build 3D cell culture vessels for stem cell applications. From 2008 to 2013 he completed a PhD on cellular capsules technology and applications at the Institut Curie in Paris.
Kévin Alessandri is CEO, CTO and co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Alessandri spent two years as a post-doctoral fellow at Bordeaux’s Institut d’Optique. During 2014 and 2015, he completed a post-doctorate at the University of Geneva, focused on developing 3D printed microfluidics systems to build 3D cell culture vessels for stem cell applications. From 2008 to 2013 he completed a PhD on cellular capsules technology and applications at the Institut Curie in Paris.
Co-founder of Meatable
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
Co-founder, CEO of Meatable
Krijn De Nood is the Dutch co-founder and CEO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology with the use of pluripotent stem cells, where he has worked since 2018. He previously worked at McKinsey for six-and-a-half years in Amsterdam, New York and in Kenya. Prior to that, he worked as an equity derivatives trader at derivative trading company All Options after a short stint at Barclays Capital.De Nood holds two first degrees from the University of Amsterdam, in philosophy and in economics and finance.
Krijn De Nood is the Dutch co-founder and CEO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology with the use of pluripotent stem cells, where he has worked since 2018. He previously worked at McKinsey for six-and-a-half years in Amsterdam, New York and in Kenya. Prior to that, he worked as an equity derivatives trader at derivative trading company All Options after a short stint at Barclays Capital.De Nood holds two first degrees from the University of Amsterdam, in philosophy and in economics and finance.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Jeffrey Leiden is a physician and scientist of more than 40 years, who is currently the executive chairman of US-based multinational biotech company Vertex Pharmaceuticals. Leiden is also the chairman of Casana, a remote healthcare platform and the chairman of Tmunity, a biotech dedicated to T-cell research. In March 2021, he participated as an angel investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Jeffrey Leiden is a physician and scientist of more than 40 years, who is currently the executive chairman of US-based multinational biotech company Vertex Pharmaceuticals. Leiden is also the chairman of Casana, a remote healthcare platform and the chairman of Tmunity, a biotech dedicated to T-cell research. In March 2021, he participated as an angel investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Meatable’s proprietary OPTi-OX technology is a pioneer in enabling scalable cell-based production of entire meat joints, 100% animal-free, starting with pork and beef.
Meatable’s proprietary OPTi-OX technology is a pioneer in enabling scalable cell-based production of entire meat joints, 100% animal-free, starting with pork and beef.
New York-based Humboldt Fund invests in startups with the potential to solve critical issues of our time across the areas of food production, healthcare, energy, and construction and manufacturing materials. It currently has 14 companies in its portfolio. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the February 2021 $16m seed round of US biotech Cellino Biotech.
New York-based Humboldt Fund invests in startups with the potential to solve critical issues of our time across the areas of food production, healthcare, energy, and construction and manufacturing materials. It currently has 14 companies in its portfolio. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the February 2021 $16m seed round of US biotech Cellino Biotech.
Founded in 2016, Berlin-based investor BlueYard invests in startups aiming to tackle the planet’s greatest challenges. It typically makes $1m–3m as an initial investment and has no geographical bias. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech and in the February 2021 $4m seed round of Next Matter, a German Open Source automation tool for operations teams.
Founded in 2016, Berlin-based investor BlueYard invests in startups aiming to tackle the planet’s greatest challenges. It typically makes $1m–3m as an initial investment and has no geographical bias. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech and in the February 2021 $4m seed round of Next Matter, a German Open Source automation tool for operations teams.
Founded in 2011, London-based Agronomics Limited’s principal investing interest is in environmentally-friendly alternatives to the traditional production of meat, wherever they may be located. There are currently 17 companies in its portfolio, all of them in the cellular-based or plant-based protein category and sustainable food production.Its most recent declared investments have been in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the December 2020 undisclosed pre-seed round of Chinese cellular foodtech CellX.
Founded in 2011, London-based Agronomics Limited’s principal investing interest is in environmentally-friendly alternatives to the traditional production of meat, wherever they may be located. There are currently 17 companies in its portfolio, all of them in the cellular-based or plant-based protein category and sustainable food production.Its most recent declared investments have been in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the December 2020 undisclosed pre-seed round of Chinese cellular foodtech CellX.
Taavet Hinrikus is the Estonian-born co-founder and CEO of money transfer platform and unicorn TransferWise (now called Wise). He was formerly Skype’s Director of Strategy and is a prolific angel investor across sectors and technologies, with investments in around 30 startups to date. His most recent investments include in the April 2021 $11m Series A round of automatic contract negotiator PACTUM and in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Taavet Hinrikus is the Estonian-born co-founder and CEO of money transfer platform and unicorn TransferWise (now called Wise). He was formerly Skype’s Director of Strategy and is a prolific angel investor across sectors and technologies, with investments in around 30 startups to date. His most recent investments include in the April 2021 $11m Series A round of automatic contract negotiator PACTUM and in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Founder of TreeFrog Therapeutics
Maxime Feyeux is President, CSO and co-founder of TreeFrog Therapeutics whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Feyeux worked as a maturation engineer at Aquitaine Science Transfert and completed a post-doctoral degree at Bordeaux’s Institut des Maladies Neurodégénératives. He also has a post-doctoral degree from the University of Geneva and completed his PhD in neurobiology and neurosciences at the Université d’Evry-Val d’Essone.
Maxime Feyeux is President, CSO and co-founder of TreeFrog Therapeutics whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Feyeux worked as a maturation engineer at Aquitaine Science Transfert and completed a post-doctoral degree at Bordeaux’s Institut des Maladies Neurodégénératives. He also has a post-doctoral degree from the University of Geneva and completed his PhD in neurobiology and neurosciences at the Université d’Evry-Val d’Essone.
DSM Venturing is the investment arm of major Dutch biotech company DSM that has been investing in startups since 2006. The company currently has 36 startups in its portfolio across geographies and has managed three exits to date. It typically invests between €100,000 and €5m, with a lifetime investment varying from €1m–20m and usually requires board membership alongside investment. It has offices in the Netherlands and the US, both on the east and west coast. Its recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the same month, in the $8m Series A round of British anti-pollution biotech Deep Branch Biotechnology.
DSM Venturing is the investment arm of major Dutch biotech company DSM that has been investing in startups since 2006. The company currently has 36 startups in its portfolio across geographies and has managed three exits to date. It typically invests between €100,000 and €5m, with a lifetime investment varying from €1m–20m and usually requires board membership alongside investment. It has offices in the Netherlands and the US, both on the east and west coast. Its recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the same month, in the $8m Series A round of British anti-pollution biotech Deep Branch Biotechnology.
Founder of TreeFrog Therapeutics
Jean-Luc Treillou is co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Since January 2019, he has also acted as an advisor and member of the strategic committee of IT security company Eshard. Prior to co-founding TreeFrog, Treillou founded YSOPIA Bioscience in 2011, where he was CEO until he left in 2021, and Chairman of the Board from 2018. Between 2009 and 2013 he held the posts of General Manager and Chairman of the Board at French R&D company Nutrionix.
Jean-Luc Treillou is co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Since January 2019, he has also acted as an advisor and member of the strategic committee of IT security company Eshard. Prior to co-founding TreeFrog, Treillou founded YSOPIA Bioscience in 2011, where he was CEO until he left in 2021, and Chairman of the Board from 2018. Between 2009 and 2013 he held the posts of General Manager and Chairman of the Board at French R&D company Nutrionix.
Founded in Silicon Valley by serial investor and founder of Google Ventures Bill Marris, Section 32 has multiple investment interests with medicine and biotech key amongst them. Marris himself has invested in over 500 companies, with over one-third resulting in IPO or M&A. Fifty of his portfolio companies have exceeded $1bn valuations, including Uber. Section 32 currently has 48 companies in its portfolio. Its most recent investments have included in Canadian remote medicine platform Cover Health’s $43m Series B round and in the $100m Series B round of US cancer detection software C2i Genomics, both in April 2021. In March 2021, it participated in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Founded in Silicon Valley by serial investor and founder of Google Ventures Bill Marris, Section 32 has multiple investment interests with medicine and biotech key amongst them. Marris himself has invested in over 500 companies, with over one-third resulting in IPO or M&A. Fifty of his portfolio companies have exceeded $1bn valuations, including Uber. Section 32 currently has 48 companies in its portfolio. Its most recent investments have included in Canadian remote medicine platform Cover Health’s $43m Series B round and in the $100m Series B round of US cancer detection software C2i Genomics, both in April 2021. In March 2021, it participated in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
UPDATED - Coronavirus: Indonesian startups launch tracking and healthcare tools, financial support
Amid a weak public health system, Indonesia's startups try to plug the gap with healthcare and monitoring tech solutions, while edtech and other online platforms see surge in demand amid social distancing
Findster: Portuguese pet tech corners the market
The number one pet location and activity tracker on Amazon, Findster has seen off cheaper rivals with its unique offer
Xurya: Pioneering solar power as a service in Indonesia with a leasing model
Targeting corporate customers without need for any upfront payment, two-year-old Xurya has already attracted major clients, and investment from Clime Capital’s impact investment fund SEACEF
Allozymes wants to supercharge manufacturing with engineered enzymes
The Future Food Asia 2021 award winner speeds up enzyme engineering from years to months, is already attracting clients and has just raised $5m seed funding
US non-profit investor New Energy Nexus seeks to kickstart Indonesia’s clean energy sectors
With a “patient capital” approach to investments and a variety of programs, New Energy Nexus hopes to show that startups can lead the way in renewables and smart energy
Xu Jinghong: Champion of young entrepreneurs and high-tech startups
Under Xu Jinghong’s leadership, Tsinghua Holdings grew its assets sevenfold and incubated over 10,000 businesses. In his new role as VC investor, Xu wants to nurture startups into future global leaders
AquaCultured Foods: World's first whole-cut vegan seafood made through microbial fermentation
Armed with its fermentation technology and proprietary strain of fungi, AquaCultured is closing an oversubscribed funding round, raising more than $1.5m to launch its non-GMO seafood alternatives, with plans to expand to more food verticals and overseas
New sectors, strategies come into play as investors respond to China's Big Tech curbs
Amid the crackdown on China’s tech giants, some investors are sussing out less risky sectors, while heavyweights like BlackRock and Fidelity stay in for the long haul
QOA: Gourmet guilt-free chocolate, without the cocoa
Munich-based QOA transforms industrial food waste into vegan chocolate, enabling consumers to avoid the sustainability and ethical issues of cocoa production
New Food Invest: Challenges of growing an alt-protein startup
Founders of three alt-protein startups in the US share what motivated them to start, their personal experiences growing the businesses, getting funding and finding strategic partners
Sorry, we couldn’t find any matches for“Stem cell”.
POPULAR DATABASE
